deCODE Receives Illumina CSPro(TM) Certification for Delivering Top Quality SNP Genotyping Services.SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- Illumina (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ILMN) announced today that deCODE genetics deCODE genetics, Inc. (Íslensk erfðagreining in Icelandic) NASDAQ: DCGN is a biopharmaceutical company based in Reykjavík, Iceland. The company was founded in 1996 to identify human genes associated with common diseases using population studies, and apply the , which operates the world's largest services facility offering Illumina single-nucleotide polymorphisms (SNP SNP Scottish National Party Noun 1. SNP - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily ) genotyping services, has received Illumina Certified Service Provider (CSPro) certification for Infinium([R]) Genotyping. Illumina, a San Diego-based company, provides next-generation tools for the large-scale analysis of genetic variation and function. deCODE, a global leader in applying human genetics Human genetics A discipline concerned with genetically determined resemblances and differences among human beings. Technological advances in the visualization of human chromosomes have shown that abnormalities of chromosome number or structure are surprisingly to develop better medicine, has partnered with Illumina to provide unique, high-value content for the Infinium Genotyping BeadChip, delivering industry-leading results for genotyping service customers. "We chose Illumina because their data quality is the best in the industry, and through our genotyping services we can in turn offer this level of quality to our customers around the world. Our Disease Miner([TM])informatics suite further provides our customers with a user-friendly means of performing their own data management and statistical analyses," said Jeff Gulcher, deCODE's Chief Scientific Officer. "Receiving CSPro certification underscores deCODE's commitment to providing the best and most comprehensive genotyping and analytical solutions, speeding the discovery process for our customers." "deCODE is the largest laboratory to offer Infinium Genotyping services, serving a growing list of customers in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. , Europe, and Asia. They are also the first company outside of North America to achieve Illumina CSPro certification for Infinium Genotyping," said Karen Possemato, Illumina's Director of Corporate Marketing. "By contributing its unrivalled expertise in human genetics, deCODE has helped to ensure that next generation Infinium Genotyping products lead the industry in quality and content." About Illumina CSPro Illumina CSPro is a collaborative service provider partnership dedicated to ensuring the delivery of the highest-quality data available for genetic analysis applications. Illumina CSPros undergo a rigorous two-phase certification process that includes minimum data generation requirements, data certification and on-site audit of the facility and processes. For more information about the CSPro program, please visit www.illumina.com/cspro. About Illumina Illumina (www.illumina.com) is developing next-generation tools for the large-scale analysis of genetic variation and function. About deCODE Genotyping Services deCODE operates the largest and most advanced high-throughput genotyping facility in the world, supported by its renowned scientists in genetics, robotics, statistics, and informatics. The company has extensive experience in providing genotyping services and has developed powerful software tools to help its customers speed the discovery process. deCODE provides a full range of services, including Infinium platform SNP genotyping, with a capacity of 3 billion SNPs per month; microsatellite See miniaturized satellite. genotyping for genome-wide scans and fine-mapping; and DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. sample preparation. For more information, please visit our website at www.decode.com/genotyping. "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina's litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. with Affymetrix, our ability to effectively integrate our recent acquisition of Solexa, Inc., Illumina's ability to further develop and commercialize its BeadArray technologies and to deploy new gene expression and genotyping products and applications for its platform technology, Illumina's ability to manufacture robust Sentrix[R] arrays and Oligator[R] oligonucleotides, Illumina's ability to scale and integrate CyVera technology, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion